Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
130.00    -0.40 (-0.31%)
Bid:
129.60
Ask:
129.80
Spread: 0.20 (0.154%)
Market Cap: £316.44m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
27th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Nov 202012:00 pmRNSVedanta Appoints Karuna CFO Troy Ignelzi to BOD
23rd Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th Nov 20207:00 amRNSPRTC LYT-100 Shows PK & Tolerability Ph1 POC
16th Nov 20207:00 amRNSPureTech to Present at Three Investor Conferences
13th Nov 20205:05 pmRNSGuidance for Exchanging Ordinary Shares into ADSs
13th Nov 20205:00 pmRNSDirector/PDMR Shareholding
13th Nov 20201:04 pmRNSGelesis Presents New Data at The Liver Meeting
13th Nov 20207:00 amRNSPureTech to Commence Nasdaq Trading on 16 November
12th Nov 20202:04 pmRNSSonde Respiratory Portal Available to Developers
11th Nov 20201:03 pmRNSVor Licenses Clinical-Stage CD33 CAR-T Therapy
5th Nov 20207:00 amRNSPureTech Presents at Credit Suisse Conference
3rd Nov 20205:10 pmRNSGelesis Presents New Data at ObesityWeek
2nd Nov 20204:35 pmRNSDirector/PDMR Shareholding
28th Oct 20207:00 amRNSPureTech Files Publicly for Nasdaq Listing
21st Oct 20201:03 pmRNSAkili Presents New Data on EndeavorRx at AACAP
20th Oct 20201:08 pmRNSVor Appoints Biotech Leader Matt Patterson to BOD
12th Oct 20201:00 pmRNSNew Vedanta VE202 Data Presented at UEG Week
7th Oct 20201:03 pmRNSAkili Adds Award-Winning Marketing Leader as CMO
5th Oct 202012:00 pmRNSAlivio Awarded $3.3M from DoD to Advance ALV-304
1st Oct 20207:05 amRNSPureTech Appoints Biocon Founder Kiran Shaw to BOD
1st Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20202:00 pmRNSBARDA Awards Vedanta Up to $76.9M to Advance VE303
29th Sep 202012:00 pmRNSAlivio Adds Dr Harry Leider to Board of Directors
25th Sep 20204:35 pmRNSPrice Monitoring Extension
23rd Sep 20207:00 amRNSPureTech Nasdaq Listing Progresses
18th Sep 20204:41 pmRNSSecond Price Monitoring Extn
18th Sep 20204:35 pmRNSPrice Monitoring Extension
18th Sep 202010:15 amRNSPrice Monitoring Extension
16th Sep 20201:00 pmRNSVedanta Appoints Drug Development Leader as CMO
4th Sep 202012:42 pmRNSGelesis Presents Plenity Efficacy and Safety Data
4th Sep 202012:07 pmRNSSecond Price Monitoring Extn
4th Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Sep 202012:02 pmRNSPrice Monitoring Extension
28th Aug 20204:40 pmRNSSecond Price Monitoring Extn
28th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Aug 20207:00 amRNSHalf-year Report
26th Aug 20201:02 pmRNSVor Appoints John King as Chief Commercial Officer
26th Aug 202012:40 pmRNSPRTC Receives $100M from Founded Entity Shares
26th Aug 202012:08 pmRNSPublication of Shareholder Circular
25th Aug 20202:05 pmRNSSonde Makes Acquisition in Vocal Biomarker Space
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20207:00 amRNSPureTech to Present at Wedbush PacGrow Conference
3rd Aug 20207:00 amRNSTotal Voting Rights
30th Jul 20201:02 pmRNSVor Appoints Life Science Leader to BOD
30th Jul 202012:07 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
21st Jul 202012:08 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.